Abstract: The present invention relates to dietary supplements, medical foods, or pharmaceutical compositions for use in the method of enhancement of cognitive function in healthy subjects and/or subjects person suffering from a cognitive deficit, comprising aqueous solution of a nutrient, wherein solution comprises a water having content of deuterium from 90 to about 135 ppm and 1H216O isotopologue up to 99.759%. In one embodiment of the invention relates to a succinate salt of choline as the nutrient.
Type:
Application
Filed:
June 29, 2015
Publication date:
December 31, 2015
Inventors:
Igor Anatolievich Pomytkin, Anton Chernopiatko, Larisa Andreeva
Abstract: An apparatus for portable delivery of nitric oxide without the need for pressurized tanks, power supplies, or other devices provides a single therapy session by triggering a heater to heat a reaction chamber. A piercing assembly may trigger to open sealed containers, such as bags, of liquid water or salt water in order to activate the heaters. Upon addition of liquid such as water or salt water to a chemically reactive heating element, heat is generated to activate the chemicals generating nitric oxide within a sealed reactor. Upon triggering, liquid containers are unsealed, the liquid drains down to initiate reaction of the heating chemicals, and the heat begins to penetrate the reactor. The reactor, in turn, heats its contents, which react to form nitric oxide expelled by the reactor to a line feeding a cannula for therapy.
Abstract: The present invention provides a method for accelerating bone growth in a subject having a bone condition, selected from the group consisting of a fracture by external force, pathological fracture, fatigue fracture, distraction osteogenesis, osteotomy, osseointegration and combinations thereof, the method employing the administration of a composition containing stable amorphous calcium carbonate, comprising at least one stabilizer. Further provided are the orally-administrable pharmaceutical compositions for use in accelerating bone growth in said bone conditions.
Type:
Application
Filed:
February 10, 2014
Publication date:
December 31, 2015
Inventors:
Oren MEIRON, Galit SHALTIEL-GOLD, Michal DANIELY
Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred composition has at least 95% ZS-9. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. These compositions are also useful in the treatment of chronic kidney disease, coronary vascular disease, diabetes mellitus, and transplant rejection.
Type:
Application
Filed:
June 26, 2015
Publication date:
December 31, 2015
Inventors:
Donald Jeffrey KEYSER, Alvaro F. Guillem
Abstract: The present invention relates to the combination of a nitroprusside salt or a solvate thereof with a sulfide salt or a solvate thereof for use in the treatment or prevention of a cardiovascular disease/disorder, such as heart failure, heart attack or hypertension.
Type:
Application
Filed:
January 31, 2014
Publication date:
December 31, 2015
Inventors:
Ivana IVANOVIC-BURMAZOVIC, Milos FILIPOVIC
Abstract: The present invention provides a method of testing a dog to determine the likelihood that the dog is protected from liver copper accumulation, comprising detecting in a sample the presence or absence in the genome of the dog of one or more polymorphisms selected from (a) SNP ATP7a_Reg3_F_6 (SEQ ID NO:142) and (b) one or more polymorphisms in linkage disequilibrium with (a).
Abstract: Implantable, malleable calcium phosphate compositions are provided. The compositions include calcium and phosphate reactants and a non-aqueous liquid carrier. Aspects of the invention also include methods of making and using the compositions, as well as kits that include the compositions. The compositions and methods find use in a variety of applications, including the repair of hard tissue defects, e.g., bone defects.
Type:
Application
Filed:
June 17, 2015
Publication date:
December 31, 2015
Inventors:
David C. Delaney, Sahil Jalota, Duran N. Yetkinler
Abstract: This invention relates to a composition that comprises inositol phosphates and/or bisphosphonates, and to the use thereof to prevent the loss of substances of biological interest in the body of patients subjected to dialysis and to maintain sufficient physiological levels of said substances to regulate physiological and/or pathological processes, these substances being inhibitors of pathological crystallisation.
Type:
Application
Filed:
September 11, 2015
Publication date:
December 31, 2015
Inventors:
Félíx GRASES FREIXEDAS, Joan PERELLO BESTARD, Fernando TUR ESPINOSA, Antonia COSTA BAUZA, Rafael M. PRIETO ALMIRALL, Isabel GOMILA MUÑIZ
Abstract: A method of manufacturing a healing and multifunctional natural gel using mineral somatid quantum energy living bodies (QELBs). The composite material including mineral somatid is produced by separating mineral somatid from the mineral, culturing the separated mineral somatid, and combining the cultured mineral somatid with powder. The composite material is harmless, has no biological side effects, has multiple functions including cancer suppression, immune enhancement, skin reconstruction, self-heating, cold activeness, VOC deodorization and harmful electromagnetic radiation shielding and absorption, and serves to increase flavor and beneficial components by promoting fermentation and ripening.
Abstract: The present invention relates to expanded NK cells. The NK cells have been expanded ex vivo, are activated and have a cytotoxic phenotype. The cytotoxicity against malignant cells is markedly increased compared to non-expanded NK cells. The invention also relates to a method of treatment.
Abstract: This invention relates to the use of mesenchymal stem cells in therapy. In particular it relates to a method of preparing the cells with enhanced immunosuppressive property and for use in the treatment of diseases of the immune system.
Abstract: Various aspects and embodiments of the present invention are directed to methods of treating a subject having an ocular condition, methods of isolating ocular stem cells, methods of selecting and/or producing ocular grafts for transplantation, and methods of promoting ocular cell regeneration as well as to grafts and preparations containing isolated ocular stem cells characterized by the expression of ABCB5 on their cell surface.
Type:
Application
Filed:
February 19, 2014
Publication date:
December 31, 2015
Applicants:
VA BOSTON HEALTHCARE SYSTEM, SCHEPENS EYE RESEARCH INSTITUTE, CHILDREN'S MEDICAL CENTER CORPORATION
Inventors:
Markus H. Frank, Natasha Y. Frank, Bruce Ksander
Abstract: The present invention relates to compositions and methods utilizing hair follicle derived Non-Bulbar Dermal Sheath cells for use in the treatment or prevention of the tendon injuries.
Abstract: Compositions and methods of using cells derived from umbilical cord tissue, to stimulate and support angiogenesis, to improve blood flow, to regenerate, repair, and improve skeletal muscle damaged by a peripheral ischemic event, and to protect skeletal muscle from ischemic damage in peripheral vascular disease patients are disclosed. In particular, methods of treating a patient having a peripheral vascular disease by systemic administration of umbilical derived cells are disclosed.
Type:
Application
Filed:
September 4, 2015
Publication date:
December 31, 2015
Applicant:
DePuy Synthes Products, Inc.
Inventors:
Charito S. Buensuceso, Anthony J. Kihm, Sridevi Dhanaraj, Roee Atlas, Israel Nur, Roberto Meidler, Liliana Bar
Abstract: A composition for the topical treatment of sores, lesions, ulcers, and other disorders of the skin, said composition includes a combination of a bee product and caffeine. The bee product may comprise bee pollen, bee propolis, honey, or royal jelly. Variations of the composition may also contain a tannin. The composition may be in the form of an ointment or cream that is applied topically to an affected area of the body. The composition may also be used in other forms, such as a spray, shampoo, soap, lipstick, or adhesive bandage. The invention may also be useful as a health beverage.
Abstract: Methods, agents and compositions thereof for treating psoriatic arthritis (PsA) and psoriasis (Ps) are encompassed herein, as are methods for identifying pathogenic dysbiosis in a subject, the presence of which is a positive indicator of risk for developing PsA or of the presence of PsA in a subject with arthritic symptoms.
Type:
Application
Filed:
April 9, 2015
Publication date:
December 31, 2015
Inventors:
Jose U. Scher, Carles Ubeda, Dan R. Littman, Eric G. Pamer, Steven B. Abramson
Abstract: The present invention provides freeze-dried compositions that include an extract of human feces and a cryoprotectant, and methods for making and using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.
Type:
Application
Filed:
September 10, 2015
Publication date:
December 31, 2015
Inventors:
Michael J. Sadowsky, Alexander Khoruts, Matthew James Hamilton, Aleh Bobr, Alexa Rachel Weingarden
Abstract: The present invention provides Leuconostoc mesenteroides NTM048 strain deposited under accession No. NITE BP-1519, or a mutant strain thereof or a processed bacterium thereof, and a lactobacillus preparation and an immunity (particularly intestinal immunity) stimulant, containing the lactobacillus or a processed bacterium thereof.
Abstract: The invention relates to acetylcholine-producing microorganisms for use in the prevention and/or treatment of intestinal diseases, and/or reduction of risks of intestinal diseases, and/or improvement of intestinal health as well as promoting healthy gut flora. The acetylcholine-producing microorganisms may be provided as a pharmaceutical dosage form or as additive to functional food or food supplemental products. Also encompassed is a method for the production of acetylcholine by use of Lactobacilli. Further the invention refers to microbially produced acetylcholine for use in the treatment and/or prevention of intestinal diseases.
Type:
Application
Filed:
February 4, 2014
Publication date:
December 31, 2015
Applicant:
LUDWIG STOCKER HOFPFISTEREI GMBH
Inventors:
Jürgen MAYER, Dirk HALLER, Anna ZHENCHUK, Thomas HOFMANN, Andreas DUNKEL, Michael SCHEMANN, Dagmar KRÜGER
Abstract: Subject of the invention is a food composition comprising Lactobacillus, or a Lactobacillus preparation, which comprises Lactobacillus cell walls, cell wall fragments and/or cell wall constituents, which is capable of aggregating Helicobacter pylori under physiological conditions, and a carrier, wherein the carrier comprises skim milk. Subject of the invention are also methods for producing such food compositions and uses thereof.
Type:
Application
Filed:
February 5, 2014
Publication date:
December 31, 2015
Applicant:
ORGANOBALANCE GMBH
Inventors:
Karen T. ROBINS, Judith MAZOTTI, Kurt GASSER
Abstract: The present invention provides Lactobacillus plantarum CJLP133 KCTC 11403BP, a composition for treating intestinal diseases comprising the lactic acid bacteria, and a composition for enhancing immunity comprising the lactic acid bacteria.
Type:
Application
Filed:
August 21, 2015
Publication date:
December 31, 2015
Inventors:
BONG JOON KIM, HEON WOONG JUNG, SE HEE HWANG, JIN HEE LEE, KANG-PYO LEE, KWANG WOO HWANG, TAE JOON WON
Abstract: An adenovirus comprising an E1A polypeptide comprising one or more modifications and comprising an E4orf6/7 polypeptide comprising one or more modifications is described. Compositions and kits comprising the modified adenoviruses are also described. Further described is a method of treating a proliferative disorder in a subject comprising administering to the subject an adenovirus comprising the E1A polypeptide comprising one or more modifications and comprising the E4orf6/7 polypeptide comprising one or more modifications.
Abstract: A method of treating cancer is disclosed, the method comprising simultaneous or sequential administration of a virus and a receptor tyrosine kinase (RTK) inhibitor.
Abstract: The present invention relates to a mainly herbal composition comprising Terminalia bellerica fruits (1-5% w/w) more particularly the extract of dried fruits. The composition further has exogenously added malonic acid, glutamic acid, eicosenoic acid and linolenic acid. The composition of present invention is useful in treatment and control of gastro intestinal problems like diarrhea, dysentery, ulcers etc. and used as an oral dosage form.
Abstract: Disclosed is a topical skin composition comprising an effective amount of Malpighia punicifolia (acerola) extract, Myrciaria dubia (camu camu) extract, and Ribes nigrum (black currant) extract, and a dermatologically acceptable vehicle comprising water, glycerin, dimethicone or cyclomethicone, stearic acid, carbomer, and sodium hydroxide.
Abstract: A cannabinoid troche including polyethylene glycol (or other base ingredients such as gelatin and/or pectin) and oils of peppermint, ginger, citrus, mango, etc., that is administered buccally and/or sublingually. This dosage form demonstrates an improved efficacy with reduced side effects when compared to formulations of cannabinoids in capsules, oral solutions, tinctures, sprays and edibles. The troches avoid harmful preservatives (e.g., BHT, BHA), heavy metals and stabilizers while addressing sub-therapeutic dosing and optimizing the synergistic qualities of the ratios of the individual cannabinoids, terpenes and flavonoids. The use of peppermint oil (and others) in the troche shows improved efficacy above and beyond that which is expected or seen without its use. The troches further allow for accurate and reproducible therapeutic effects with ease of dosage adjustments.
Abstract: The present invention provides a composition for skin regeneration including chamomile hydrosol prepared by vacuum distillation as an active ingredient. The composition for skin regeneration including camphor or chamomile hydrosol prepared by vacuum distillation, which contains the camphor, exhibits to excellent skin regeneration ability to promote proliferation and migration of skin cells, and simultaneously include only components derived from natural herbal plants, and thus can be used in various forms such as medicine, quasi-drugs, cosmetics, and food materials without any of side effects.
Abstract: Antiseptic pharmaceutical composition useful for the treatment of painful lesions in oral mucosa, ulcerative and inflammatory lesions of different origin and the treatment and/or prevention of oral mucositis and stomatitis.
Abstract: The present invention provides a method of treating neuropathic pain by administering a topical homeopathic composition to a mammalian subject. The homeopathic formulation contains homeopathic active ingredients comprising Hypericum perforatum in a base of essential oils which facilitate delivery of the homeopathic ingredient through the skin.
Abstract: An anti-viral composition comprising terpenes and fatty acids found in the Scophulariaceae family of plants is disclosed. It further comprises other lipophillic constituents and the aglycons of the glycosides occurring in said family of plants. Preferably, the composition is derived by extraction of the roots and rhizomes of mixtures of Picrorhiza kurrooa Royle, Picrorhiza scrophularflora Pennell and Neopicrorhiza scrophula iflora. Solvents and solvent combinations are disclosed. The composition is effective against both DNA and RNA viruses and against fungal, bacterial, parasitic and protozoal infections and diseases and also as a hepatoprotective, anti-hyperlipidemic, anti-diabetic and kidney-protective agent. Anti-bodies and vaccines for the cited diseases can be made by administration of the composition to animal or other subjects.
Abstract: A topical composition includes a polymer matrix containing sodium hyaluronate and a nonionic polymer, the polymer matrix being suspended in a liquid medium; and a therapeutically effective amount of a nutraceutical entity dispersed in suspension within the polymer matrix, wherein the molar ratio of the sodium hyaluronate to the nonionic polymer is 1:0.5 to 4, the sodium hyaluronate being present in amounts of about 2.0% to about 3.5% by weight of the composition. Other topical compositions and uses thereof are disclosed.
Abstract: The present invention provides a fermented dried material derived from the fermented liquid obtainable by fermenting wheat germ with Saccharomyces cerevisiae in an aqueous medium for use in the treatment of inflammatory bowel disease. Methods of treating and/or preventing an inflammatory bowel disease are also described.
Abstract: The present invention relates to the novel use of panduratin derivatives or an extract of Boesenbergia pandurata for enhancing muscle mass growth, fighting fatigue and enhancing exercise performance, and more particularly to a composition for promoting an increase in muscles, anti-fatigue composition and a composition for enhancing muscle mass growth and recovery from fatigue to improve exercise performance, the composition comprising a panduratin derivative or a salt thereof or an extract of Boesenbergia pandurata as an active ingredient, and to a method for enhancing muscle mass growth, of treating or preventing fatigue syndrome and enhancing exercise performance, the method comprising a panduratin derivative or a salt thereof or a extract of Boesenbergia pandurata to a subject in need thereof.
Abstract: A pharmaceutical composition for treating cancers and preparation method thereof. Said composition for treating cancers contains Chinese medicinal materials including Rhizoma Pinelliae, Rhizoma Arisaematis, Rhizoma Gastrodiae etc., and said preparation method is in accordance with a conventional Chinese medicinal preparation method, manufacturing said composition to form any one of the ordinary oral preparations.
Abstract: The invention relates to pharmaceutical compositions and methods for treating Meniére's Disease. In particular, the invention provides a method for treating Meniére's Disease in a subject in need thereof by administering a pharmaceutical composition comprising a peptide inhibitor of c-Jun N-terminal kinase.
Abstract: The present invention relates to compositions comprising peptides that may be variants, derivatives and structural equivalents of cupredoxins that inhibit the development of premalignant lesions in mammalian cells, tissues and animals. Specifically, these compositions may comprise azurin from Pseudomonas aeruginosa, and/or the 50-77 residue region of azurin (p28). The present invention further relates to compositions that may comprise cupredoxin(s), and/or variants, derivatives or structural equivalents of cupredoxins, that retain the ability to inhibit the development of premalignant lesions in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to prevent the development of premalignant lesions in mammalian cells, tissues and animals, and thus prevent cancer.
Abstract: The present disclosure provides targeting peptides and vectors containing a sequence that encodes targeting peptides that deliver agents to the brain.
Abstract: Provided is a solid composition which has reduced bad taste and offensive odor and provides good taste and flavor, while containing wheat albumin at a high concentration. A solid composition comprising the following components (A) and (B): (A) wheat albumin, and (B) alanine or a salt thereof, wherein a mass ratio of a content of the 0.19-wheat albumin (a) in the solid composition to a content of the alanine or a salt thereof in terms of alanine (b) in the solid composition, [(a):(b)], is from 250:1 to 10:1.
Abstract: Controlled studies demonstrate that products and related methods using soy related peptides lower total and LDL cholesterol levels in individuals. In one exemplary embodiment of the present disclosure, a product containing an effective amount of lunasin peptides that lowers cholesterol levels in an individual that consumes the lunasin peptides is provided. In another exemplary embodiment of the present disclosure, a composition containing an effective amount of lunasin peptides or lunasin peptide derivatives and one or more enzyme inhibitors is provided. In a related exemplary embodiment of the present disclosure, a method for lowering or reducing cholesterol levels in an individual is provided where a product containing an effective amount of lunasin peptides to an individual is provided and a claim that the product lowers or reduces cholesterol, total cholesterol, LDL cholesterol or lipid levels in an individual that consumes the composition is made.
Abstract: Described herein are methods of protecting germ cells in a subject from cell death induced by a chemotherapeutic agent by, in part, administering a composition comprising one or more humanin polypeptides to the subject. Also described herein are methods of inhibiting a reduction or decrease in fertility in a subject wherein the reduction or decrease in fertility is due to a chemotherapeutic agent.
Type:
Application
Filed:
March 11, 2015
Publication date:
December 31, 2015
Inventors:
Ronald S. Swerdloff, YanHe Lue, Christina Wang
Abstract: Peptide compounds based on the CAP37 protein are disclosed, along with methods for treating various infections, wounds, and conditions, and methods of promoting healing and acceptance of grafts, using compositions containing these peptides.
Type:
Application
Filed:
December 3, 2013
Publication date:
December 31, 2015
Applicant:
The Board of Regents of the University of Oklahoma
Inventors:
Heloise Anne Pereira, Anne Kasus-Jacobi, Gina L. Griffith
Abstract: The present invention is related to compositions and methods to treat, ameliorate and/or prevent morbidity and/or mortality from microbial infections. In particular, bacterial infections that are associated with the production and release of bacterial toxins. For example, many Clostridia bacteria, such as Clostridium difficile, release toxins resulting in tissue and organ damage and death, even after antibiotic therapy that either reduces or eliminates the bacteria. In particular, various peptides, polypeptides, and proteins are disclosed herein that either inactivate Clostridium difficile toxin and/or reduce Clostridium difficile toxin production.
Abstract: The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl 1, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ?-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.
Type:
Application
Filed:
June 30, 2015
Publication date:
December 31, 2015
Inventors:
David J. ELLIS, George P. Miljanich, David E. Shields
Abstract: The present invention relates to an agent for the treatment and/or prophylaxis of an autoimmune disease, an agent for the formation of regulatory T cells (TReg) in an organism and various methods in which the agents according to the invention are used.
Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
Type:
Application
Filed:
February 18, 2014
Publication date:
December 31, 2015
Applicants:
GANYMED PHARMACEUTICALS AG, TRON-Translationale Onkologie an der Universitats- medizin der Johannes Gutenberg-Universitat Mainz.
Inventors:
Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.
Type:
Application
Filed:
June 30, 2015
Publication date:
December 31, 2015
Inventors:
Bai Liu, Peter Rhode, Wenxin Xu, Hing C. Wong
Abstract: The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein.
Type:
Application
Filed:
July 1, 2015
Publication date:
December 31, 2015
Inventors:
Robert Rosa, Gavin W. Roddy, Darwin J. Prockop
Abstract: A method of treating or preventing cognitive impairment deficits in subjects with age-associated cognitive decline or a dementing illness includes administering to the subject a therapeutically effective amount of amylin, an amylin agonist, or an amylin derivative to treat the cognitive impairment or deficit.
Type:
Application
Filed:
September 14, 2015
Publication date:
December 31, 2015
Inventors:
Gemma Casadesus Smith, Brittany Adler, Mark Yarchoan
Abstract: This document provides diuretic and natriuretic polypeptides. For example, this document provides polypeptides having diuretic and/or natriuretic activities. In some cases, a polypeptide provided herein can have diuretic and natriuretic activities, while lacking the ability to lower blood pressure. This document also provides methods and materials for inducing diuretic and/or natriuretic activities within a mammal.
Type:
Application
Filed:
September 14, 2015
Publication date:
December 31, 2015
Applicant:
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Inventors:
Robert D. Simari, Shuchong Pan, John C. Burnett, JR., Horng H. Chen
Abstract: The invention relates to novel stable and protracted GLP-1/glucagon receptor co-agonists, to the use of said peptides in therapy, to methods of treatment comprising administration of said peptides to patients, and to the use of said peptides in the manufacture of medicaments.
Type:
Application
Filed:
August 26, 2015
Publication date:
December 31, 2015
Inventors:
Ulrich Sensfuss, Thomas Kruse, Jesper F. Lau